Pharmaceutical company AbbVie will unveil its first-quarter earnings Thursday, giving investors and industry observers their first glimpse of what a full quarter of sales looks like for its new hepatitis C treatment.
Spending in the U.S. on prescription drugs rose by 13% in 2014, driven largely by increased spending on new breakthrough medications, according to a new report. And Medicaid patients' spending on drugs rose much faster in states that expanded Medicaid under the ACA compared with those that did not.
If left untreated, Stacey Lane's level of bad cholesterol would soar to more than four times what heart experts recommend. Help for her genetic disorder could come in the form of a new category of injectable drugs known as PCSK9 inhibitors, but it won't be cheap.
New cost-effectiveness analyses of Sovaldi and other treatments to treat chronic hepatitis C infection suggest U.S. firms initially set prices near the ceiling that the United Kingdom's National Health Service will pay for drugs.
The emergence of new specialty breakthrough medications has come with a hefty price tag that may demand alternative financing approaches to ensure they remain accessible to patients, a new analysis suggests.
Financial markets have sent another signal that the coming era of precision or personalized medicine could wind up making cancer care unaffordable for millions of people.
Healthcare spending grew faster than the rest of the economy last year despite the ongoing reduction in hospital use and an industrywide campaign to hold down costs. How can that be?
Mark Ganz, president and CEO of Cambia Health Solutions, a not-for-profit parent of 22 companies offering healthcare products and services, discusses how his companies are seeking to make healthcare more consumer-directed.
David Cade, a former top attorney at HHS, has been appointed CEO of the American Health Lawyers Association.
The soaring sales and profits reported by Gilead Sciences in 2014 aren't likely to be repeated as the company begins to offer steeper discounts on its blockbuster hepatitis C treatments Sovaldi and Harvoni.
Gilead Sciences, the Foster City, Calif.-based drugmaker, said sales of its blockbuster hepatitis C duo topped $3.8 billion in the fourth quarter of 2014, fueling quarterly revenue that doubled to $7.3 billion and $3.5 billion in profits.
The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.